Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.
Nicola PuglieseVincenza CalvarusoMario MasaroneRoberta D'AmbrosioSara BattistellaAnna LicataMarcello PersicoMaria Paola AnolliMarco DistefanoSalvatore PettaFrancesco Paolo RussoVito Di MarcoAlessio AghemoPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
Treatment with G/P achieved 97.9% SVR rates in HCV patients older than 75 years of age. Safety was optimal with only 2% of patients discontinuing early.